Viral B2 protein increases output from self-amplifying RNA in cells
A laboratory study found that Nodamura virus B2 protein helped self-amplifying RNA produce more target protein despite cellular antiviral defenses. The restriction differed between stem cells and differentiated cells, while immune signaling remained detectable. This is a molecular result in experimental cells; no vaccine protection or human safety outcome was measured.
Science··Evening
Self-copying RNA meets antiviral defenses
Self-amplifying RNA is designed to keep producing a target protein after it enters a cell. Its copying process also creates double-stranded RNA, a signal that cells can recognize as viral material. That defense can cut the experimental RNA or interrupt translation before much target protein is made. Researchers at Queen Mary University of London tested whether a protein from Nodamura virus, called B2, could reduce those restrictions without erasing immune stimulation.[1], [2]
B2 raises protein output by different routes
In mouse embryonic stem cells, active B2 reduced signs that the Dicer pathway was chopping the RNA into smaller pieces. In differentiated human cell lines, it limited a different brake: PKR-related shutdown of protein translation. A B2 variant unable to bind double-stranded RNA served as a comparison. Target-protein output rose in the experiments, while the reported interferon response remained detectable rather than being fully suppressed.[1]
Cell results leave vaccine performance open
The Nature Communications work examined experimental RNA constructs and cells, not vaccinated people. Queen Mary describes the finding as a possible route toward later vaccine development and says the team is seeking a commercial partner. Different dominant defenses in stem cells and differentiated cells also mean that one cellular result cannot stand for every tissue. Protection, safety, useful dose and lasting immunity would require further work beyond the reported laboratory experiments.[1]
